MIRTIMASH 30MG 30 CAP; mirtazapine, antidepressants .
MIRTIMASH 30MG 30 CAP
ACTIVE-INGREDIENT OF MIRTIMASH 30MG
EACH scored film coated tablet contains mirtazapine 30 mg .
INDICATION OF MIRTIMASH 30MG
treatment of depressive illness .
DOSAGE OF MIRTIMASH 30MG
Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet
Ask your pharmacist or doctor for help if you do not understand the instructions on the box .
The recommended dose is : –
mirtimash tablets should be taken orally , if necessary with fluid . And swallowed without chewing . Adults : treatment should begin with 15 mg daily . The dosage generally needs to be increased to obtain an optimal clinical response . The effective daily dose is is usually between 15 and 45 mg . elderly : the recommended dose is the same as that for adults . in elderly patients , an increase in dosing should be done under close supervision to elicit a satisfactory and safe response . children : since safety and efficacy of mirtazapine has not been established in children , it is not recommended to treat children with mirtazpine tablets . renal and hepatic insufficiency : the clearance of mirtazapine may be decreased in patients with renal or hepatic insufficiency . this should be taken into account when prescribing mirtazapine has a half – life of 20-40 hours and therefore mirazapine tablets are suitable for once – a day administration preferably as a single night-time dose before goning to bed . mirtazapine tablets may also be given in sub – doses equally divided over the day ( once in the morning and once at night – time ) . treatment should preferably be continued until the patient has been completely symptom – free for 4-6 months . after this , treatment can be gradually discontinued . treatment with an adequate dose should result in a positive response within 2-4 weeks . with an insufficient response , the dose can be increased up to the maximum dose . if there is no response within a further 2-4 weeks , then treatment should be stopped . withdrawal symptoms seen on discontinuation of mirazapine : abrupt discontinuation should be avoided . if intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment . then resuming the previously prescribed dose may be considered . subsequently , the physician may continue decreasing the dose , but at a more gradual rate .
OVER-DOSAGE OF MIRTIMASH 30MG
reports of overdose with mirtazapine alone indicate that the symptoms are usually mild . Depression of the central nervous system with disorientation and prolonged sedation have been reported , together with tachycardia and mild hyper – or hypotension . cases of overdose should be treated by gastric lavage with appropriate symptomatic and supportive therapy for vital functions .
CONTRA-INDICATION OF MIRTIMASH 30MG
hypersensitivity to mirtazapine or any of the other ingredients of mirtazapine tablets .
STORAGE OF MIRTIMASH 30MG 30 CAP
Store at temperature not exceeding 30 °C , in dry place . Keep out of reach of children .
PACK OF MIRTIMASH 30MG 30 CAP
carton box containing 1, 2 or 3 ( AL/ transparent PVC ) strips , each of 10 tablets and inner leaflet .
MIRTIMASH 30MG 30 CAP MANUFACTURED BY
MASH PREMIEREE
https://www.webmd.com/drugs/2/drug-13706-4047/mirtazapine-oral/mirtazapine-oral/details
Reviews
There are no reviews yet